Background Single nucleotide polymorphisms (SNPs) in angiotensinogen (AGT) at positions -20 and -6 are associated with increased severity and progression of various fibrotic diseases. Our earlier work demonstrated that the progression of idiopathic pulmonary fibrosis (IPF) was associated with the A-6 allele. This study examined the hypothesis that the homozygous CC genotype at -20 and the AA genotype at -6 would confer worse measures of pulmonary function (measured by pulmonary function tests) in IPF. Methods Multiple logistic regression analysis was applied to a NIH Lung Tissue Research Consortium cohort and a Spanish cohort, while also adjusting for covariates to determine the effects of these SNPs on measures of pulmonary function. Results Analysis demonstrated that the CC genotype at -20 was strongly associated with reduced diffusing capacity in males in both cohorts (p = 0.0028 for LTRC and p = 0.017 for the Spanish cohort). In females, the AA genotype was significantly associated with lower FVC (p = 0.0082) and V alv (p = 0.022). In males, the haplotype CA at -20 and -6 in AGT was also strongly associated with reduced diffusing capacity in both cohorts. Conclusions This study is the first to demonstrate an association of AGT polymorphisms (-20A [ C and -6G [ A) with lower measures of pulmonary function in IPF. It is also the first to relate the effect of gender in lung fibrosis with polymorphisms in AGT.
Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease. It is a ''chronic, progressive, and irreversible'' condition with a bias toward males and people in their fifth through eighth decade of life [1] . Upon diagnosis, the mean survival is 3 years. Currently, the only therapy that can prolong survival is lung transplantation [1] , but the 5-year postoperative survival rate is 44 % [1] . The other current modes of therapy (corticosteroids and immunosuppressants) are of minimal benefit to IPF patients. This reflects the incomplete knowledge underlying the pathogenesis of IPF and paves the way for novel therapies to address this void [2] .
A strong predictor of mortality in IPF is the number of myofibroblastic foci [3] . Myofibroblasts play an important role in lung fibrosis. They can be derived from a variety of sources, including pericytes, fibrocytes, epithelial or endothelial cells, and normal lung fibroblasts, which, when stimulated with transforming growth factor (TGF)-b 1 , differentiate into myofibroblasts. Myofibroblasts within many tissues are a known source of collagen and angiotensin II (ANGII), and the ANGII produced by myofibroblasts is known to mediate fibrogenesis in various organ systems such as the heart, kidney, liver, pancreas, skin, and lung [4] [5] [6] [7] [8] [9] [10] . ANGII is derived from its precursor angiotensinogen (AGT), and both AGT and ANGII have been shown by this laboratory to be required for experimental lung fibrosis [11, 12] . ANGII also enhances TGF-b 1 synthesis in human lung myofibroblasts isolated from patients with IPF [9] . In turn, TGF-b 1 is able to stimulate AGT transcription in myofibroblasts, thus creating an ''ANGII-TGF-b 1 autocrine loop'' in myofibroblasts [9] . This laboratory also demonstrated that TGF-b 1 -inducible AGT transcription is regulated through two transcription factors, JunD and HIF1a, both of which act on binding domains in the core promoter of AGT in the region spanning from -46 to ?22 from the transcription start site [13] .
The core promoter also contains three single nucleotide polymorphisms (SNPs) located at -20, -18, and -6. The SNPs at these locations have been shown to result in changes in AGT transcription rate in nonpulmonary cell types. In hepatocytes, the presence of the CC haplotype at -20 and -18 increased AGT transcription to more than twofold when compared to the AT haplotype [14] . Similarly, the presence of the A allele at -6 increased AGT transcription in comparison to the G allele at the same position [15] . These SNPs have also been associated with the severity and/or progression of various diseases, including IgA nephropathy, hepatic fibrosis and cirrhosis, hypertension, and IPF [16] [17] [18] [19] [20] [21] . In a Spanish IPF cohort, our laboratory demonstrated that the AA genotype of -6G [ A was significantly associated with disease progression as measured by alveolar-arterial oxygen gradient over time [20] .
Based on this, it was hypothesized that the presence of the CC genotype at -20 and/or the AA genotype at -6, particularly when found together, would confer worse measures of pulmonary function in IPF as measured by pulmonary function tests (PFTs). In accordance with this hypothesis, it was theorized that the presence of both of these alleles would confer a ''risk haplotype'' for IPF; the risk haplotype was predicted to be CA (at the -20 and -6 positions, respectively).
Methods

Subjects
The Lung Tissue Research Consortium (LTRC) provided 163 blood samples and over 1,100 associated clinical variables from IPF patients. From these, samples that were unable to be genotyped and samples that were missing variables of interest were excluded. The final pool consisted of 149 samples and 68 variables of interest that came from the categories of demographics, tobacco use, environmental exposure, disease history, medications, pulmonary function tests, and arterial blood gases. This pool was composed of 94 males and 55 females [age = 63.4 ± 8.5 and 62.4 ± 9.2 (mean ± SD), respectively]. Similar analyses were performed on a second cohort consisting of 203 patients from a Spanish population. This group was composed of 123 males and 80 females [age = 66.1 ± 10.6 and 67.5 ± 13.1 (mean ± SD), respectively].
Genotyping Polymorphisms at -20 and -6
The genotyping protocol was derived from Jeunemaitre et al. [22] 
Statistical Analysis
The relationship between measures of pulmonary function (as measured by PFTs, including FEV 1 , FVC, FEV 6 , mean DLCO, V alv , and KCO) and the genotyped SNPs at -20 and -6 was tested by fitting regression models assuming different gene action modes (i.e., additive, dominance, and recessive) after adjusting for the effects of covariates. Data analysis was done with statistical software R (ver. 2.13.2). From the original 163 individuals, 14 individuals were excluded because their samples were unable to be genotyped or their variables of interest were missing. To account for possible gender differences in disease progression, missing phenotypic values were imputed using the mean value of the corresponding phenotype for male and female data separately. Analysis for the Spanish cohort was done in a similar manner except for the inclusion of covariates (due to the lack of collection of these variables).
All the phenotypes (as measured by PFTs) were individually analyzed. A stepwise variable selection was initially performed in R on all covariates for each phenotype. The selected covariates were then fitted into the genetic models (Supplementary Table 1 ) together with the SNP variables. For each phenotype, roughly 10-15 covariates were left after variable selection. Three genetic models representing different gene action modes were considered in this study (the joint model analyzing the whole population is in Supplementary Table 1 ). In practice, the true disease model is unknown. Statistically, a model selection criterion can be used to choose which genetic model fits the data best. The Akaike information criterion (AIC) was used to select the optimal model, which is defined as AIC = -2 log L ? 2 k, where L is the regression likelihood and k is the total number of parameters fitted in the model. The model with the minimum AIC value was chosen as the optimal one. For the three models, testing a SNP effect is equivalent to testing H 0 : b 1 = b 12 = 0, a 2 degrees-offreedom (df) likelihood ratio test, while adjusting for the effects of other covariates. The likelihood ratio statistic asymptotically follows a v 2 distribution with 2 df. For each phenotype, multiple-testing adjustment was done for the two position. Thus, any SNP with p \ 0.025 was considered statistically significant by maintaining a familywise error rate of 0.05. To assess whether male and female populations have different genetic bases in determining worse measures in pulmonary functions, the above models were modified by removing the sex covariate as well as the genetic-by-sex interaction term (the sex-specific model in Supplementary Table 1 ) and were fitted to the male and female data separately. The same set of covariates fitted with the male and female combined data was fitted into the modified models. A likelihood ratio test was applied to test the significance of the regression coefficients after selecting the optimal model using the AIC criterion. A power study revealed that the datasets have [90 % power to detect a mean difference [0.7 between the largest and smallest means among the three genotype groups with a sample size of 55, the smallest sample size in our study (females in the LTRC cohort). Table 1 summarizes the age and mean pulmonary function test values for the LTRC and the Spanish population subjects for which all genotyping and function test data were available. The data are separated by gender in accordance with the finding of gender-specific differences in the association between AGT genotype and PFT values, which is discussed below. No statistically significant differences were observed between males and females in any of the data reported in Table 1 .
Results
Characteristics of the Patient Population
Genotype and Allele Frequencies
The genotype and allele frequencies for the -20A [ C and -6G [ A polymorphisms in AGT are summarized in Tables 2 and 3 . No statistically significant differences were observed in the allele frequencies at the -20 or -6 position between men and women ( Table 3) .
Influence of AGT Genotype on Pulmonary Function Tests: Whole-Population Analysis
In an analysis of each cohort as a whole (Table 4 , i.e., without separation by gender), the CC genotype at -20 was most strongly associated with reduction of KCO in both cohorts. However, the impact of gender on this measure was also significant (see below). The AA genotype at -6 also was associated with reduction of KCO. Table 4 lists only those PFT data for which statistically significant differences were observed in this analysis.
Influence of AGT Genotype on Pulmonary Function Tests: Gender-specific Analyses When the whole population was reanalyzed with sample separation by gender, several gender-specific effects of AGT genotype on PFT values were revealed. In the male IPF population (Table 5) , the CC genotype at the -20 position was associated with a very strong reduction in KCO (from 3.19 ± 0.84 to 1.46 ± 0.34) of high statistical significance (p = 0.0028) in the LTRC cohort. This effect was also seen in the Spanish cohort [ Table 5 (p = 0.017)]. The AA genotype at -6 also was associated with reduced KCO in males, but with lower statistical significance (p = 0.0214) in the LTRC cohort.
In females (Table 6 ), significant associations were seen only at the -6 position; the -20 position had no apparent effect. The AA genotype at -6 was associated with a reduction in FVC (p = 0.0081) and V alv (p = 0.022) in the LTRC cohort. However, in the Spanish cohort, this genotype was associated with an increase in diffusing capacity (p = 0.023). As discussed further below, the lack of decrease in KCO may be related to the large decrease in V alv that is associated with the AA genotype at -6 in females (p = 0.022).
Analysis of an ''IPF Risk Haplotype''
Multiple-position analysis revealed that in males, the AGT haplotype CA (at -20 and -6, respectively) was strongly associated with reduced KCO in both the LTRC cohort (p = 0.0048) and the Spanish cohort (p = 0.014). This association was not statistically significant in females. Interestingly, the AG haplotype at -20 and -6 also was associated with reduced KCO in males in the LTRC cohort, but at a lower statistical significance (p = 0.031). When the combined male and female data were analyzed, no significant haplotype was found. 
Discussion
The Influence of AGT Genotype on Pulmonary Function Tests in IPF Given that diffusing capacity for carbon monoxide is the best noninvasive clinical measure of the thickness of the alveolar-capillary diffusion barrier, it was theorized that diffusing capacity would be decreased the most in individuals with AGT genotypes already associated with hypertension and/or higher rates of AGT transcription in other organs. In males with IPF, this proved to be the case; the lowest KCO values were observed in individuals with the genotypes CC at -20 and AA at -6. The most drastic decrease was observed with the CC genotype at -20, with which the KCO decreased more than twofold compared to the AA genotype (Table 5 ). In males, FEV 1 and FVC also increased, rather than decreased, with the CC genotype at the -20 position; this might be due to more forceful expirations assisted by the increased elastic recoil imparted by the fibrotic lung parenchyma. Unfortunately, it was not possible to explore this hypothesis further with the LTRC dataset. Regardless, in females with IPF, the lowest FVC and V alv values and highest KCO were observed in individuals with the AA genotype at -6 (Table 6 ). These data are consistent with our earlier observations [21] .
Influence of Gender on the Effects of the -20 and -6 Positions on PFTs in IPF IPF is known to affect men more than women, but little is known about the cause of this gender difference. This study is the first to report an association of genetic variants in AGT at the -20 and -6 positions, at both the genotype and haplotype level, with gender. On the genotype level, the male gender had a stronger effect at the -20 position, while the female gender imparted a greater effect at the -6 position. Other authors who studied nonpulmonary systems have also observed gender-specific effects of AGT variants, e.g., Chapman et al. [24] demonstrated that the -6 position was also more significantly associated with increased carotid intimal medial thickening in the female population. In the present study, haplotype analysis revealed that the IPF ''risk haplotype'' CA was significant only in males (the AG haplotype was also significant but to a lesser degree). Although other authors have noted an additional, albeit rare, SNP in AGT at the -18 position [14] , the -18 position was genotyped here but was not analyzed further due to the lack of this variant in the LTRC or Spanish cohort.
AGT Promoter Sequence Variants and Transcription Rate
In studies of AGT synthesis by isolated human hepatocytes, SNPs at the -20 and -6 positions influence the transcription rate of AGT mRNA [14, 15] . The transcription rate is higher with the C allele at -20 and the A allele at -6. In earlier studies of animal models of lung fibrosis and isolated lung cells, transcription of the AGT gene has been shown to be required for the fibrogenic response to bleomycin and for the apoptotic response of alveolar epithelial cells to a number of profibrotic stimuli [9, 12] . Taken together, these findings suggest, and indeed had led us to hypothesize, that higher rates of AGT transcription in lung cells imparted by the CA haplotype would lead to worse lung fibrosis in IPF patients, as indicated by reductions in KCO, DLCO, or FVC. As discussed above, most of these effects were found in this study, but in a surprising genderdependent manner. Hormonal regulatory elements located in the same AGT promoter domain as the SNPs studied here also influence the transcription rate of AGT. Of particular interest is the estrogen response element that is located in the AGT promoter region spanning -11 to -25 [25] . Estrogen receptor alpha (ER-a) preferentially binds to the -20 position if the A nucleotide is present and induces an increase in AGT transcription by human liver cells [25] . Estrogen also mediates fibrogenesis by upregulating the transcription of procollagen I and TGF-b 1 [ 26] . TGF-b 1 stimulates fibroblasts to transition into myofibroblasts, which in turn deposit collagen and express AGT constitutively [9, 13] . Another mechanism that might regulate AGT differentially by gender is if the estrogen receptor binding to the AGT promoter prevents the binding of other transcription factors that might otherwise up-or downregulate AGT transcription. Conversely, the binding domain of the orphan receptor Arp-1 shares homology to the binding domain for ER-a [27] . The binding of Arp-1 to this domain reduces estrogeninduced AGT transcription [27] . These data suggest that the balance between estrogen and Arp-1 at the -20 position may thus be an influential factor in this gender discrimination. In males, it is possible that the balance may favor estrogeninduced AGT transcription instead of repression by Arp-1. IPF affects people in their fifth to eighth decade of life, and women in these decades tend to be postmenopausal. In this stage estrogen levels drop; this may explain the bias for males at the -20 position. In males with IPF, the KCO decreased with the presence of CC genotype at -20, while in females there was an increase in the KCO at this same position. Thus, the balance between ER-a and Arp-1 may play a role in this difference. This topic will be an interesting issue for future investigation.
Another possible explanation for this gender difference is the potential role of androgens in AGT transcription. Throughout the human life span, androgen receptors (ARs) are expressed in both mesenchymal and epithelial cells. In studies of the prostate gland, ANGII enhanced the expression of ARs through the ANGII type-1 receptor [28] , and one of the downstream effects of this cascade is prostate cell proliferation. If this model is applicable to the lung, modulation of ARs might also contribute to increased severity of IPF in males. For these reasons, the potential role of androgens in the gender differences that AGT variants exert on IPF severity will also be an interesting topic for further research.
In this regard it is important to note that if human, mouse, and rat AGT promoter sequences are compared, there is relatively low homology between these species in the TGF-b 1 responsive domain of AGT between the TATA box and the transcription initiation site [13] . Due to these sequence differences, human lung cells in culture should remain an important model to complement and extend the studies reported here. Moreover, caution should be exercised in attempts to extrapolate data on the regulation of AGT expression obtained from animal models to human lung fibrosis.
